 Daily Mail | UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine The Pharma Letter The Appraisal Committee considered that the most plausible Incremental Cost Effectiveness Ratio (ICER) for cabazitaxel in combination with prednisone or prednisolone would be above £87500 ($141391) per QALY gained. The drug did meet the criteria to be ... NICE gives final rejection to Sanofi's Jevtana for prostate cancer |
